Delstudie 06E: Paraplyundersøgelse af kombinationsterapier ved esophageal cancer (MK-3475-06E/KEYMAKER-U06)
En fase 1/2 Open-Label, paraplyplatformdesignundersøgelse af undersøgelsesmidler i kombination med Pembrolizumab (MK-3475) med eller uden kemoterapi hos deltagere med 1L lokalt avanceret uoperabel/metastatisk spiserørskræft: KEYMAKER-U06 Delstudie 06E
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts.
Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing.
Researchers want to learn about giving pembrolizumab and investigational agents, with or without chemotherapy to treat ESCC. Ifinatamab deruxtecan (I-DXd), is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells.
The main goal of this study is to learn about the safety of investigational agents and pembrolizumab with or without chemotherapy and if people tolerate them. Researchers also want to learn how cancer responds (gets smaller or goes away) to the study treatments.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The master protocol is MK-3475-U06.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studiesteder
-
-
-
São Paulo, Brasilien, 01246-000
- Rekruttering
- ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1302)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 551138932000
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasilien, 59062-000
- Rekruttering
- Liga Norte Riograndense Contra o Cancer ( Site 1301)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +55 84 4009-5595
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 91010-004
- Rekruttering
- Hospital Nossa Senhora da Conceicao ( Site 1300)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +555133572092
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 03102-002
- Rekruttering
- IBCC - Instituto Brasileiro de Controle do Cancer ( Site 1303)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 551144500300
-
-
-
-
-
Antofagasta, Chile, 1263521
- Rekruttering
- Bradford Hill Norte ( Site 1405)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56442023631
-
-
Los Lagos Region
-
Port Montt, Los Lagos Region, Chile, 5500243
- Rekruttering
- Clínica Puerto Montt ( Site 1406)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56652484800
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7620002
- Rekruttering
- Clínica UC San Carlos de Apoquindo ( Site 1403)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56223748924
-
Santiago, Region M. de Santiago, Chile, 8420383
- Rekruttering
- Bradfordhill ( Site 1401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56220490970
-
Santiago, Region M. de Santiago, Chile, 7560913
- Rekruttering
- Centro de Oncología de Precisión ( Site 1402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56972151681
-
Santiago, Region M. de Santiago, Chile, 7500921
- Rekruttering
- Fundación Arturo López Pérez ( Site 1400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +56224205098
-
-
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- UPMC Hillman Cancer Center ( Site 1904)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 412-623-8974
-
-
-
-
-
Paris, Frankrig, 75013
- Rekruttering
- Pitie Salpetriere University Hospital ( Site 9102)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +331 42 16 10 41
-
-
Finistere
-
Brest, Finistere, Frankrig, 29609
- Rekruttering
- C.H.R.U. de Brest - Hopital Cavale Blanche ( Site 9104)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 33298223428
-
-
Nord
-
Lille, Nord, Frankrig, 59037
- Rekruttering
- CHU Lille - Institut Coeur Poumon ( Site 9100)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +33320445461
-
-
-
-
Lombardy
-
Milan, Lombardy, Italien, 20132
- Rekruttering
- Ospedale San Raffaele-Oncologia Medica ( Site 9201)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390226437615
-
-
Veneto
-
Padova, Veneto, Italien, 35128
- Rekruttering
- Istituto Oncologico Veneto IRCCS ( Site 9202)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 390498215910
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Rekruttering
- Aichi Cancer Center ( Site 9702)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-52-762-6111
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East ( Site 9701)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-4-7133-1111
-
-
Tokyo
-
Chūō, Tokyo, Japan, 104-0045
- Rekruttering
- National Cancer Center Hospital ( Site 9700)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +81-3-3542-2511
-
-
-
-
Anhui
-
Hefei, Anhui, Kina, 230601
- Rekruttering
- The Second Affiliated Hospital of Anhui Medical University ( Site 9511)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0551-63839536
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 130021
- Rekruttering
- Beijing Cancer Hospital ( Site 9500)
-
Kontakt:
- Study Coordinator
- Telefonnummer: (010)88196317
-
-
Fujian
-
Xiamen, Fujian, Kina, 361003
- Rekruttering
- The First Affiliated Hospital of Xiamen University ( Site 9503)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0592-2139767
-
-
Henan
-
Zhengzhou, Henan, Kina, 450008
- Rekruttering
- Henan Cancer Hospital ( Site 9509)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 0371-65587625
-
-
Jiangsu
-
Xuzhou, Jiangsu, Kina, 221000
- Rekruttering
- Xuzhou Central Hospital ( Site 9512)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 86051680812397
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330006
- Rekruttering
- The First Affiliated Hospital of Nanchang University ( Site 9505)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 86079188692201
-
-
-
-
-
Oslo, Norge, 0379
- Rekruttering
- Oslo Universitetssykehus Radiumhospitalet ( Site 1501)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4723026600
-
-
-
-
-
Geneva, Schweiz, 1211
- Rekruttering
- Hopitaux Universitaires de Geneve HUG. ( Site 1701)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +41 (0)22 372 95 77
-
-
Kanton Graubünden
-
Chur, Kanton Graubünden, Schweiz, 7000
- Rekruttering
- Kantonsspital Graubuenden ( Site 1700)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +41 81 256 61 11
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapore, 119074
- Rekruttering
- National University Hospital ( Site 9800)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +65 6908 2222
-
-
-
-
-
Seoul, Sydkorea, 05505
- Rekruttering
- Asan Medical Center ( Site 9901)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82230107179
-
Seoul, Sydkorea, 06351
- Rekruttering
- Samsung Medical Center ( Site 9900)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82234106518
-
-
Kyonggi-do
-
Goyang-si, Kyonggi-do, Sydkorea, 10408
- Rekruttering
- National Cancer Center ( Site 9902)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +82319201694
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Rekruttering
- Kaohsiung Chang Gung Memorial Hospital ( Site 1003)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +88677317123x3679
-
Taichung, Taiwan, 40707
- Rekruttering
- China Medical University Hospital ( Site 1007)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 886-4-22052121
-
Tainan, Taiwan, 704302
- Rekruttering
- National Cheng Kung University Hospital ( Site 1001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +88662353535x4559
-
Taipei, Taiwan, 100225
- Rekruttering
- National Taiwan University Hospital ( Site 1000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +886223123456x67680
-
Taipei, Taiwan, 11217
- Rekruttering
- Taipei Veterans General Hospital ( Site 1005)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +886228712121
-
Taipei, Taiwan, 106
- Rekruttering
- National Taiwan University Cancer Center ( Site 1010)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 886223220322
-
Taoyuan, Taiwan, 33305
- Rekruttering
- Chang Gung Memorial Hospital - Linkou Branch ( Site 1006)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +88633281200 #8825
-
-
Kaohsiung
-
Kaoshiung, Kaohsiung, Taiwan, 807
- Rekruttering
- Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 1009)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +8867-3121101#7451
-
-
-
-
Bangkok
-
Ratchathewi, Bangkok, Thailand, 10400
- Rekruttering
- Ramathibodi Hospital ( Site 1103)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6622004029
-
-
Changwat Songkhla
-
Hat Yai, Changwat Songkhla, Thailand, 90110
- Rekruttering
- Songklanagarind hospital ( Site 1101)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +6674451469
-
-
-
-
Brno-mesto
-
Brno, Brno-mesto, Tjekkiet, 656 53
- Rekruttering
- Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 9000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +420543136812
-
-
-
-
-
Adana, Tyrkiet (Türkiye), 01140
- Rekruttering
- Adana Medical Park Seyhan Hastanesi ( Site 9404)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90444 44 84
-
Ankara, Tyrkiet (Türkiye), 06520
- Rekruttering
- Memorial Ankara Hastanesi ( Site 9406)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905456177189
-
Ankara, Tyrkiet (Türkiye), 06230
- Rekruttering
- Hacettepe Universite Hastaneleri ( Site 9401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905333319240
-
Ankara, Tyrkiet (Türkiye), 06800
- Rekruttering
- Ankara Bilkent Şehir Hastanesi ( Site 9403)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +90 312 552 60 00
-
Erzurum, Tyrkiet (Türkiye), 25070
- Rekruttering
- Atatürk Üniversitesi ( Site 9405)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +905543701653
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Tyskland, 69120
- Rekruttering
- NCT-Department of Medical Oncology ( Site 1809)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +49 62215637784
-
-
Free and Hanseatic City of Hamburg
-
Erdgeschoss, Free and Hanseatic City of Hamburg, Tyskland, 22297
- Rekruttering
- HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 1807)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +4940360352246
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Tyskland, 40225
- Rekruttering
- Universitaetsklinikum Duesseldorf ( Site 1808)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +492118108751
-
-
Saxony
-
Dresden, Saxony, Tyskland, 01307
- Rekruttering
- Universitätsklinikum Carl Gustav Carus - Medical Oncology ( Site 1806)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +493514583016
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
The main inclusion criteria include but are not limited to the following:
- Has histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic squamous cell carcinoma of the esophagus in first-line (1L) setting.
- Has measurable disease per RECIST 1.1 as assessed by the local site. investigator or designee/radiology assessment and verified by BICR. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
- Has had AEs due to previous anticancer therapies that have recovered to ≤Grade 1 or baseline. Endocrine-related AEs that are adequately treated with hormone replacement are elegible.
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Has adequate organ function.
Exclusion Criteria
The main exclusion criteria include but are not limited to the following:
- Has had systemic anticancer therapy for locally advanced unresectable or metastatic esophageal cancer.
- Has tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of fistula.
- Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention.
- Has clinically significant corneal disease, history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
- Has received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor.
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention.
- Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids.
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
- Has inadequate cardiac function assessed as by a corrected QT interval by Fredericia (QTcF) value ≥470 msec.
- Has clinically significant cardiovascular disease within 6 months from first dose of study intervention, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
- Has peripheral neuropathy ≥ Grade 2.
- Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Has active autoimmune disease that has required systemic treatment in the past 2 years.
- Has had a history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), has a current diagnosis of ILD, or has clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out.
- Has active infection requiring systemic therapy.
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Pembrolizumab + Chemotherapy
Participants will receive 400 mg of pembrolizumab via intravenous (IV) infusion every six weeks (Q6W) on Day 1 of each 42-day cycle up to 18 cycles (up to approximately 2 years), and mFOLFOX6 chemotherapy: oxaliplatin 85 mg/m^2 via IV infusion every 2 weeks (Q2W), until progressive disease (PD) or toxicity; leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 via IV infusion Q2W, until PD or toxicity; 5-fluorouracil (5-FU) 400 mg/m^2 bolus IV infusion followed by 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, until PD or toxicity. |
IV infusion IV infusion
Andre navne:
IV infusion IV infusion IV Infusion |
|
Eksperimentel: Pembrolizumab + I-DXd
Participants will receive 200 mg of pembrolizumab via IV infusion Q3W on Day 1 of each 21-day cycle for up to 35 cycles (up to approximately 2 years). Participants will also receive up to 12 mg/kg I-XDd Q3W via IV infusion, until PD or toxicity. |
IV infusion
Andre navne:
IV infusion
Andre navne:
Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label |
|
Eksperimentel: Pembrolizumab + I-DXd + 5-FU IV + Leucovorin or Levoleucovorin
Participants will receive 200 mg pembrolizumab via IV infusion Q3W on Day 1 of each 21-day cycle up to 35 cycles (up to approximately 2 years). Participants will also receive I-DXd up to 12 mg/kg via IV infusion Q3W, until PD or toxicity; 5-FU 400 mg/m^2 bolus IV infusion followed by 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, OR 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, until PD or toxicity; and leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 via IV infusion Q2W, until PD or toxicity. |
IV infusion IV infusion
Andre navne:
IV infusion IV Infusion IV infusion
Andre navne:
Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label |
|
Eksperimentel: Pembrolizumab + I-DXd + 5-FU IV + Leucovorin or Levoleucovorin + Oxaliplatin
Participants will receive 200 mg of pembrolizumab via IV infusion Q3W on Day 1 of each 21-day cycle up to 35 cycles (up to approximately 2 years). Participants will also receive up to 12 mg/kg I-DXd via IV infusion q3w, until PD or toxicity; 5-FU 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, until PD or toxicity; 60mg/m^2 oxaliplatin via IV infusion Q2W, until PD or toxicity; and leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 via IV infusion Q2W, until PD or toxicity. |
IV infusion IV infusion
Andre navne:
IV infusion IV infusion IV Infusion IV infusion
Andre navne:
Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label |
|
Eksperimentel: Pembrolizumab + Sacituzumab tirumotecan + 5-FU IV + Leucovorin or Levoleucovorin
Participants will receive 400 mg pembrolizumab via IV infusion Q6W on Day 1 of each 42-day cycle up to 18 cycles (up to approximately 2 years). Participants will also receive sacituzumab tirumotecan 4 mg/kg via IV infusion Days 1, 15, and 29 every 42-day cycle, until PD or toxicity; 5-FU 400 mg/m^2 bolus IV infusion followed by 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, OR 2400 mg/m^2 continuous 46-48 hour IV infusion Q2W, until PD or toxicity; and leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 via IV infusion Q2W, until PD or toxicity. |
IV infusion IV infusion
Andre navne:
IV infusion IV Infusion Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid for Arms 2, 3, and 4, and H1 receptor antagonist, H2 receptor antagonist, acetaminophen, dexamethasone, and steroid mouthwash for Arm 5, administered per approved product label IV infusion
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants who Experience Dose Limiting Toxicities (DLTs) During the Safety Lead-In Phase
Tidsramme: Up to approximately 28 days
|
Percentage of participants experiencing toxicities that are possibly, probably, or definitely related to study intervention; that meet pre-defined severity criteria; and result in a change in the given dose. |
Up to approximately 28 days
|
|
Percentage of Participants who Experience an Adverse Event (AE)
Tidsramme: Up to approximately 77 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience an AE will be reported. |
Up to approximately 77 months
|
|
Objective Response Rate (ORR)
Tidsramme: Up to approximately 77 months
|
ORR is defined as a confirmed complete response (CR: the disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). The percentage of participants who experience CR or PR as assessed by BICR will be presented. |
Up to approximately 77 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of Response (DOR)
Tidsramme: Up to approximately 77 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. |
Up to approximately 77 months
|
|
Progression-Free Survival (PFS)
Tidsramme: Up to approximately 77 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 77 months
|
|
Overall Survival (OS)
Tidsramme: Up to approximately 77 months
|
OS is defined as the time from allocation/randomization to death due to any cause. |
Up to approximately 77 months
|
|
Disease Control Rate (DCR)
Tidsramme: Up to approximately 77 months
|
DCR is defined as a confirmed complete response (CR) or partial response (PR), or stable disease (SD) with at least 6 months PFS per RECIST 1.1 as assessed by BICR. |
Up to approximately 77 months
|
|
Maximum Plasma Concentration (Cmax) of I-DXd
Tidsramme: At designated time points up to approximately 65 months
|
Cmax is defined as the peak level I-DXd reaches in the blood plasma. Blood samples collected predose and at multiple timepoints postdose will be used to determine the Cmax of I-DXd when co-administered with other investigational agents. |
At designated time points up to approximately 65 months
|
|
Time to Maximum Plasma Concentration (Tmax) of I-DXd
Tidsramme: At designated time points up to approximately 65 months
|
Tmax is defined as the time it took I-DXd to reach its peak level in blood plasma. Blood samples collected predose and at designated timepoints postdose will be used to determine the Tmax of I-DXd when co-administered with other investigational agents. |
At designated time points up to approximately 65 months
|
|
Area Under the Concentration-Time Curve from Time 0 to Last Measurable Plasma Concentration (AUClast) of I-DXd
Tidsramme: At designated time points up to approximately 65 months
|
AUClast is defined as the area under the concentration-time curve from time 0 to the last measurable concentration of I-DXd in the blood plasma. Blood samples collected at predose and at designated timepoints postdose will be used to determine the AUClast of I-DXd in combination with other agents. |
At designated time points up to approximately 65 months
|
|
Area Under the Concentration-Time Curve from Time 0 to the End of the Dosing Period (AUCtau) of I-DXd
Tidsramme: At designated time points up to approximately 65 months
|
AUCtau is defined as the area under the concentration-time curve from time zero to the end of the dosing period. Blood samples collected at predose and at designated timepoints postdose will be used to determine the AUCtau of I-DXd in combination with other agents. |
At designated time points up to approximately 65 months
|
|
The Percentage of Participants with Antidrug Antibodies (ADA) Against I-DXd
Tidsramme: Up to approximately 65 months
|
Blood samples collected at designated timepoints will be used to determine the ADA response to I-DXd. The percentage of participants with ADA will be reported. |
Up to approximately 65 months
|
|
The Percentage of Participants with Treatment-Emergent ADA Against I-DXd
Tidsramme: Up to approximately 65 months
|
Blood samples collected at designated timepoints will be used to determine the treatment-emergent ADA response to I-DXd. The percentage of participants who have treatment-emergent I-DXd ADA will be reported. |
Up to approximately 65 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Studieleder: Medical Director, Merck Sharp & Dohme LLC
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Neoplasmer i hoved og hals
- Neoplasmer, kirtel og epitel
- Esophageale sygdomme
- Karcinom
- Neoplasmer, pladecelle
- Karcinom, pladecelle
- Esophageale neoplasmer
- Esophageal pladecellekarcinom
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Enzymer og coenzymer
- Koordinationskomplekser
- Pyrimidiner
- Formyltetrahydrofolater
- Tetrahydrofolater
- Folinsyre
- Pterins
- Pteridiner
- Uracil
- Pyrimidinoner
- Coenzymer
- Oxaliplatin
- Fluorouracil
- Leucovorin
- Levoleucovorin
- pembrolizumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 3475-06E
- MK-3475-06E (Anden identifikator: MSD)
- U1111-1307-6484 (Registry Identifier: UTN)
- jRCT2041240166 (Registry Identifier: Japan Registry of Clinical Trials (jRCT))
- 2024-514273-22-00 (Registry Identifier: EU CT)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .